Martingale Asset Management L P Sells 5,664 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Martingale Asset Management L P lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 13.2% in the third quarter, Holdings Channel reports. The firm owned 37,102 shares of the biotechnology company’s stock after selling 5,664 shares during the quarter. Martingale Asset Management L P’s holdings in United Therapeutics were worth $13,296,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. LSV Asset Management grew its position in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares during the period. FMR LLC grew its position in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after acquiring an additional 314,004 shares during the period. Assetmark Inc. grew its position in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the period. Pacer Advisors Inc. grew its position in shares of United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of United Therapeutics by 49.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after acquiring an additional 91,597 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 2.0 %

Shares of United Therapeutics stock opened at $370.49 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The company has a 50-day simple moving average of $367.42 and a two-hundred day simple moving average of $334.45. The stock has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.27, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company earned $5.38 EPS. The business’s revenue was up 22.9% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at approximately $1,108,766.10. This represents a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,227 shares of company stock worth $47,398,820 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright lifted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. The Goldman Sachs Group raised their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.